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BACKGROUND AND PURPOSE
Many cancer cells depend on anti-apoptotic B-cell lymphoma 2 (Bcl-2) proteins for their survival. Bcl-2 antagonism through Bcl-2
homology 3 (BH3) mimetics has emerged as a novel anti-cancer therapy. ABT-199 (Venetoclax), a recently developed BH3 mi-
metic that selectively inhibits Bcl-2, was introduced into the clinic for treatment of relapsed chronic lymphocytic leukaemia. Early
generations of Bcl-2 inhibitors evoked sustained Ca2+ responses in pancreatic acinar cells (PACs) inducing cell death. Therefore,
BH3 mimetics could potentially be toxic for the pancreas when used to treat cancer. Although ABT-199 was shown to kill Bcl-2-
dependent cancer cells without affecting intracellular Ca2+ signalling, its effects on PACs have not yet been determined. Hence, it
is essential and timely to assess whether this recently approved anti-leukaemic drugmight potentially have pancreatotoxic effects.
EXPERIMENTAL APPROACH
Single-cell Ca2+ measurements and cell death analysis were performed on isolated mouse PACs.
KEY RESULTS
Inhibition of Bcl-2 via ABT-199 did not elicit intracellular Ca2+ signalling on its own or potentiate Ca2+ signalling induced by
physiological/pathophysiological stimuli in PACs. Although ABT-199 did not affect cell death in PACs, under conditions that killed
ABT-199-sensitive cancer cells, cytosolic Ca2+ extrusion was slightly enhanced in the presence of ABT-199. In contrast, inhibition
of Bcl-xL potentiated pathophysiological Ca2+ responses in PACs, without exacerbating cell death.
CONCLUSION AND IMPLICATIONS
Our results demonstrate that apart from having a modest effect on cytosolic Ca2+ extrusion, ABT-199 does not substantially alter
intracellular Ca2+ homeostasis in normal PACs and should be safe for the pancreas during cancer treatment.
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Introduction
Impaired regulation of apoptosis is crucial to the process of
carcinogenesis enabling cancer cells to evade cell death sig-
nals triggered by oncogenic stress and acquiring metastatic
properties by accumulation of secondary genetic mutations
(Adams and Cory, 2007; Hanahan and Weinberg, 2011). In
cancer cells, this is achieved by altered expression levels of ei-
ther the pro- or anti-apoptotic B-cell lymphoma 2 (Bcl-2)
family members, predominantly located at the mitochon-
drial membranes (Davids and Letai, 2012). Pro-apoptotic
Bcl-2-associated X protein (Bax) and Bcl-2 homologous
antagonist killer (Bak) are critical in the initiation of mi-
tochondrial outer membrane permeabilization, the point of
no return for apoptosis induction, whereas the anti-apoptotic
Bcl-2 members [such as Bcl-2, Bcl-extra large (Bcl-xL) or Bcl-
2-like protein 2 (Bcl-w)] counteract this process (Chipuk et al.,
2008). Bcl-2-dependent cancers are often ‘primed for death’, a
term used to describe the necessity of expressing high levels
of the anti-apoptotic Bcl-2 proteins in order to actively
sequester and inhibit the pro-apoptotic family members, par-
ticularly Bax and the activator Bcl-2 homology 3 (BH3)-only
protein Bcl-2-like protein 11 (Bim) (Akl et al., 2014). There-
fore, pharmacological disruption of the interaction between
the anti- and pro-apoptotic Bcl-2 family members has the po-
tential to activate Bax/Bak, and restore the programmed cell
death (Wang et al., 2000; Chipuk et al., 2008). This spurred
the development of Bcl-2 antagonists that target the hydro-
phobic cleft of the anti-apoptotic Bcl-2 proteins displacing
Bax/Bak and Bim from Bcl-2. A very successful strategy has
been the development of so-called ‘BH3 mimetic’ molecules
that structurally resemble the BH3 domain of sensitizer
BH3-only proteins like Bad (Bcl-2-associated death pro-
moter), thereby inhibiting Bcl-2 without directly activating
Bax/Bak (Oltersdorf et al., 2005).
The early generation of BH3 mimetics, such as HA14-1
and BH3I-20, despite being able to disrupt the interaction be-
tween the pro- and anti-apoptotic proteins to initiate apopto-
sis (Wang et al., 2000; Degterev et al., 2001), had serious
limitations that prevented their translation into the clinic.
Some of these limitations have been linked to their adverse
impact on the Ca2+ signalling machinery in non-tumoural
cells that is essential for intracellular Ca2+ homeostasis, cell
function and survival (Vervloessem et al., 2018). For instance,
HA14-1 also inhibits the Ca2+-pump activity of the sarco/
endoplasmic reticulum Ca2+ ATPase (SERCA), provok-
ing cell death in part by depleting the ER Ca2+-store
(Hermanson et al., 2009; Akl et al., 2013). Moreover, both
HA14-1 and BH3I-20 were found to have pancreatotoxic ef-
fects (Gerasimenko et al., 2010; Ferdek et al., 2017). These ef-
fects were mediated directly by pathological Ca2+ responses
in pancreatic acinar cells (PACs), the secretory epithelium
that produces and releases digestive enzymes in the pancreas
(Gerasimenko et al., 2010). It is well established that excessive
Ca2+ signals underlie the pathogenesis of acute pancreatitis, a
severe human disease (Gerasimenko et al., 2018). Moreover,
dysregulation of Ca2+ homeostasis has also been implicated
in the development of acute pancreatitis provoked by the
anti-leukaemic drug L-asparaginase, which is used to treat
childhood acute lymphoblastic leukaemia (Peng et al., 2018;
Vervliet et al., 2018). In such cases, the anti-cancer therapy
must be ceased. At the mechanistic level, an excessive intra-
cellular cytosolic Ca2+ concentration ([Ca2+]i) together with
the depletion of intracellular Ca2+ stores in the ER and acidic
pools, including zymogen granules, triggers premature prote-
ase activation in situ in PACs leading to autodigestion of the
tissue (Petersen et al., 2011).
Nevertheless, the development of BH3 mimetics contin-
ued, resulting in ABT-737 and its orally available successor
ABT-263 (navitoclax), as selective on-target inhibitors of
Bcl-2, Bcl-xL and Bcl-w that are able to induce cancer cell
death (Oltersdorf et al., 2005; Del Gaizo Moore et al., 2008).
Although these two pharmacological agents were shown to
be effective at killing several Bcl-2-dependent cancer types
(Oltersdorf et al., 2005; Tse et al., 2008), they were also found
to induce thrombocytopenia and deregulate Ca2+ homeosta-
sis in platelets, effects attributed to Bcl-xL inhibition
(Schoenwaelder et al., 2011; Vogler et al., 2011). Recently,
ABT-199 (venetoclax) has been developed (Souers et al.,
2013). This orally bioavailable selective inhibitor of Bcl-2
was shown to cause cell death in chronic lymphocytic leukae-
mia (CLL) cells with an EC50 < 10 nM (Souers et al., 2013). In
2016, ABT-199 became the ﬁrst ever clinically approved small
molecule drug targeting a protein–protein interaction, and
since then it has been used in the clinic as a therapy for re-
lapsed CLL (Green, 2016). This drug is attracting a lot of inter-
est and is currently undergoing further clinical trials, often in
combination with other chemotherapeutic agents (Ferdek
and Jakubowska, 2017).
Given that several of the early BH3 mimetics have been
shown to alter intracellular Ca2+ signalling, particularly in
the pancreas (Gerasimenko et al., 2010; Ferdek et al., 2017),
it became essential and timely to determine whether or not
the recently approved anti-leukaemic drug ABT-199 and
other inhibitors such as selective Bcl-xL antagonist
A-1155463 and Bcl-2/Bcl-xL inhibitor ABT-737 show effects
that might potentially be pancreatotoxic. Although ABT-
199 was shown not to dysregulate intracellular Ca2+ signal-
ling upon acute application in the Bcl-2-dependent diffuse
large Bcl (DLBCL) cell lines (Vervloessem et al., 2017b,
2018), data on healthy primary cells are very limited. It is also
unclear whether prolonged exposure to ABT-199 could inﬂu-
ence intracellular Ca2+ signalling in normal PACs. What is
more, in PACs, physiological enzyme secretion is controlled
by [Ca2+]i oscillations triggered by ACh and cholecystoki-
nin (CCK) (Petersen and Tepikin, 2008). Therefore, it is also
important to assess whether these physiological Ca2+ signals
are affected by ABT-199. Furthermore, inducers of pancreati-
tis, such as certain bile acids, initiate pancreatic pathology
via abnormal Ca2+ responses (Gerasimenko et al., 2006;
Ferdek et al., 2016). However, potential synergistic effects be-
tween those inducers and ABT-199, which may lead to aggra-
vation of the disease, have not yet been addressed. ABT-199
has already been introduced successfully into the clinic as
an anti-leukaemic agent, and its potential therapeutic appli-
cations are likely to increase in due course. Since acute pan-
creatitis is a side effect of some (5–10% of cases) existing
therapies for acute lymphoblastic leukaemia in children
(Kearney et al., 2009; Raja et al., 2014) and Ca2+ signals have
been implicated in this process (Peng et al., 2016), it has be-
come particularly relevant to assess the impact of ABT-199
(along with the selective Bcl-xL inhibitor A-1155463 and
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the Bcl-2/Bcl-xL inhibitor ABT-737) on intracellular Ca2+ ho-
meostasis and dynamics in healthy PACs.
Methods
Animals: Housing, husbandry and
experimental procedures
Experimental animals (6-week-old male C57BL6/J mice,
23 ± 3 g) were purchased from Charles River UK and then
housed in the Cardiff University or the Jagiellonian Univer-
sity institutional animal units (12 h light cycle) and main-
tained on a standard rodent chow diet with free access to
water. Up to ﬁve mice were kept per cage with aspen wood
bedding material and an enriched environment (cardboard
tunnel, nesting material, wooden gnawing sticks, etc.). All
procedures involving animals were performed in accordance
with the UK Home Ofﬁce or the Polish Ministry of Science
and Higher Education regulations. The mice were humanely
killed by cervical dislocation according to Schedule 1 of Ani-
mals (Scientiﬁc Procedures) Act 1986. The pancreatic tissue
was removed for further experimental procedures. In order
to reduce the number of animals needed for the experiments
(in line with the 3Rs), cells isolated from one animal were
used by two researchers simultaneously.
Isolation of PACs
PAC isolation was performed as described previously
(Ferdek et al., 2017). The isolation and the experimental
work was carried out in NaHEPES buffer. Unless otherwise
stated, NaHEPES was supplemented with 1 mM Ca2+. Imme-
diately after dissection, the pancreatic tissue was washed
twice in NaHEPES, treated with collagenase (200 U·mL1, in
NaHEPES) and then enzymatically digested in the collage-
nase solution at 37°C for 15 min. After digestion, the
pancreas was broken down by pipetting, suspended in
NaHEPES, spun (1 min, 0.2 × g), resuspended in NaHEPES
and spun again. Finally, isolated cells were suspended in
NaHEPES and loaded with a Ca2+-sensitive dye, Fluo-4, as
described below.
Cytosolic Ca2+ measurements
Isolated PACs were loaded with 5 μM Fluo-4 AM [30 min, at
room temperature (RT)]. After the incubation, the cells were
resuspended in fresh NaHEPES and used for experiments
(RT) in a ﬂow chamber perfused with NaHEPES-based extra-
cellular solution. Experiments were performed using the fol-
lowing equipment: (i) Zeiss LSM 880 confocal microscope
(×63 oil objective) at the Jagiellonian University; and (ii)
Leica TCS SPE confocal microscope (×63 oil objective) or
Leica TCS SP5 II two-photon confocal microscope (×63 water
objective) at Cardiff University. Excitation was set to 488 nm
and emission to 500–600 nm. Static images were taken at
512 × 512 pixel resolution, and a series of images were re-
corded at 256 × 256 pixel resolution; two consecutive frames
were averaged, and time resolution was one image per 2 s.
Fluorescence signals were plotted as F/F0, where F0 was an av-
eraged signal from the ﬁrst 10 baseline images.
Cell death assay in PACs
Cell death assay was performed using an Annexin V-FITC/PI
apoptosis detection kit. PACs were isolated as described
above, spun down and then suspended in 3 mL of fresh
NaHEPES. The cells were divided equally into the experimen-
tal groups (ﬁnal volume of NaHEPES: 2 mL) and kept until
further treatment (4°C). Then 1 mL of the buffer was re-
moved, and the cells were treated with 1 mL of 2× concen-
trated incubation buffer containing menadione or TLC-S,
and the vehicle (2 or 4 h, RT); the isolation quality control
group was incubated with NaHEPES only. Also, in some
treatment groups, the incubation buffer at this stage was sup-
plemented with the BH3 mimetics: ABT-199, A-1155463,
ABT-199 together with A-1155463, or ABT-737. The ﬁnal con-
centrations were as follows: menadione 60 μM and TLC-S
200 μM; and the BH3 mimetics: 1 μM ABT-199, 1 μM
A-1155463, 1 μM ABT-199 together with 1 μM A-1155463,
or 10 μM ABT-737. Owing to the limited amount of mouse
PACs obtained in a single isolation procedure, all experimen-
tal groups but one were equal by design. For the cell death as-
say, the cells isolated from 16 pancreata were either treated
with NaHEPES (the isolation quality control, N = 16) or ran-
domized to the experimental groups with ﬁve independent
pancreata per group (N = 5). Since the NaHEPES-treated sam-
ple served as the control for each individual pancreas isola-
tion (16 in total) subsequently used in the cell death
experiments, Nwas 16 for this condition. Fifteen minutes be-
fore the end of the incubation, Annexin V-FITC and PI were
added to the samples. The cells were visualized with a TCS
SP5 II two-photon confocal microscope (Leica) with a 63×
1.2 NA water objective, and ﬂuorescence/transmitted light
images were taken. Annexin-V-FITC (excitation: 488 nm,
emission: 510–555 nm) speciﬁcally stains apoptotic cells,
whereas PI (excitation: 535 nm, emission: 585–650 nm) was
used for detection of necrotic cells; the cells stained with both
ﬂuorescent dyes were classiﬁed as secondary necrosis. Fifteen
pictures of independent cell clusters were taken at 512 × 512
pixel resolution. The percentage of live, apoptotic, secondary
necrotic and necrotic cells were counted in each treatment
group by one researcher in a blinded fashion (encoding the
group labels).
Cell death assay in B-cell lymphoma lines and
CLL patient samples
DLBCL cell lines were seeded at 250 000 cells·mL1 24 h be-
fore treatment. Cells were harvested at 2, 4 and 6 h after
1 μM ABT-199 or vehicle treatment and stained with Alexa
Fluor™ 488 Annexin V/7-AAD. Flow cytometry was used for
data acquisition (Attune; Thermo Fisher Scientiﬁc) whereby
viable cells were identiﬁed as being Annexin V/7-AAD nega-
tive. The analysis was performed using the FlowJo software.
Blood samples were collected from patients with CLL ac-
cording to the principles established by the International
Conference on Harmonization Guidelines on Good Clinical
Practice. An informed consent was obtained from all patients
and approval for the study was obtained from the ethical
committee of the Università Cattolica del Sacro Cuore,
Fondazione Policlinico A. Gemelli, Rome, Italy (protocol
number 14563/15). The collection and analysis of CLL pa-
tient samples were performed as reported in Bojarczuk et al.
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(2016). Brieﬂy, mononuclear cells were isolated from
peripheral blood samples by Ficoll gradient centrifugation.
The proportion of CD5+CD19+ CLL cells was determined by
ﬂow cytometry; samples containing >85% CLL cells were
used for the subsequent experiments. CLL cells were cultured
at a cell density of 1 × 107 mL1 in RPMI 1640 supplemented
with 10% heat-inactivated FBS, 100 U·mL1 penicillin,
0.1 mg·mL1 streptomycin, 2 mM L-glutamine and 1 mM so-
dium pyruvate (Invitrogen) and treated for 2, 4 or 6 h with
ABT-199 (1 μM) or vehicle. The percentage of apoptotic cells
was determined by staining with PI and annexin-A5-FITC
conjugate (Nexins Research) and analysis on an FACSCalibur
ﬂow cytometer with CellQuest Pro version 5.2.1 software (BD
Biosciences).
Comparison of Ca2+ extrusion
In order to empty the ER Ca2+ stores, PACs were treated with
2 μM thapsigargin (Tg) for 10 min in the absence of extra-
cellular Ca2+. Then the extracellular Ca2+ concentration was
increased to 10 mM, which induced Ca2+ inﬂux to the cyto-
sol. Once a [Ca2+]i plateau was achieved, removal of extracel-
lular Ca2+ unmasked the process of Ca2+ extrusion across the
plasma membrane. This phase of the response was further
analysed and compared between control and ABT-199
pretreated PACs. First, for every recorded [Ca2+]i trace, the
maximum and minimum F/F0 values in the rage of
1000–1400 s of the response were determined (Fmax and Fmin).
The normalized ﬂuorescence that corresponds to half the
decrease between these two values was calculated as follows:
F1/2 = Fmin + (FmaxFmin)/2. Next, a linear ﬁt to the extrusion
phase was determined. Time values corresponding to Fmax
(tmax) and F1/2 (t1/2) were calculated from the linear ﬁt.
Finally, t1/2 was calculated as the difference between t(F1/2)
and tmax. The t1/2 values obtained for control and ABT-
199-treated cells were then averaged and presented as dot
charts ±SEM. Student’s t-test was applied for statistical com-
parison, and the signiﬁcance threshold was set at 0.05.
Statistical analysis
The data and statistical analysis comply with the recommen-
dations on experimental design and analysis in pharmacol-
ogy (Curtis et al., 2015). At least ﬁve independent repeats
(N = 5) were performed in each experimental setting (see the
text for details). Additionally, in Ca2+ signalling experiments,
n values representing the recorded ﬂuorescence of the speciﬁc
regions of interest (ROI), corresponding to single cells, were
provided. Those were not the technical replicates but the in-
dependent measurements of the entire cell population in
the experiment. Because of the non-equal numbers cells re-
corded in the viewing ﬁelds, n may vary between treatment
groups in the given experimental setting. Quantitative analy-
sis of Ca2+ responses was performed as described previously
(Ferdek et al., 2017). Brieﬂy, areas under the individual traces
were calculated according to the formula: Σ(F/F0F0) × Δt,
where F is the recorded ﬂuorescence, F0 is the baseline ﬂuores-
cence and Δt is the time interval. The values obtained were
then averaged and presented as dot charts ±SEM. Student’s
t-test was applied for statistical comparison, and the signiﬁ-
cance threshold was set at 0.05. Quantitative analysis of cell
death was performed using SPSS Statistics 24 software (IBM):
ﬁrst, Levene’s test was used to assess the equalities of the
variances for a variable calculated for the groups, and then
ANOVA or a non-parametric Kruskal–Wallis one-way ANOVA
were applied to compare the differences among group means;
for both tests, the signiﬁcance thresholds were set at 0.05. Fi-
nally, Bonferroni’s post hoc test (whenever relevant) was per-
formed only if values of the F-test (used to assess the
equalities of the means of a given set of normally distributed
populations, all having the same SD) achieved the necessary
level of statistical signiﬁcance (P < 0.05).
Materials
The main reagents for cell isolation and imaging included:
Annexin V-FITC/propidium iodide (PI) apoptosis detection
kit, Fluo-4 AM (Thermo Fisher Scientiﬁc, Loughborough,
UK); collagenase (Worthington, Lakewood, USA); ACh,
CCK, inorganic salts, menadione, taurolithocholic acid
3-sulfate (TLC-S) (Sigma-Aldrich, Dorset, UK); and the
BH3 mimetics: the Bcl-2 inhibitor ABT-199 (Active Biochem,
Bonn, Germany), the Bcl-xL inhibitor A-1155463
(Selleckchem, Cambridgeshire, UK) and the non-selective
Bcl-2, Bcl-xL and Bcl-w inhibitor ABT-737 (Santa Cruz Bio-
technology, Heidelberg, Germany). NaHEPES buffer was pre-
pared as follows (mM): NaCl 140, KCl 4.7, HEPES 10, MgCl2
1, glucose 10; pH 7.3. The BH3 mimetics were dissolved in
DMSO, TLC-S in NaHEPES and menadione in ethanol.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are
hyperlinked to corresponding entries in http://www.
guidetopharmacology.org, the common portal for data from
the IUPHAR/BPS Guide to PHARMACOLOGY (Harding et al.,
2018), and are permanently archived in the Concise Guide
to PHARMACOLOGY 2017/18 (Alexander et al., 2017a,b,c,d).
Results
Selective inhibition of only one Bcl-2 family
member by BH3 mimetics does not induce
noxious Ca2+ responses
In order to compare the effects of acute inhibition of different
Bcl-2-protein family members on Ca2+ homeostasis in PACs,
several BH3 mimetics were tested (Figure 1). First, 10 μM
ABT-737 was used to target the hydrophobic clefts of a wide
range of Bcl-2 proteins: Bcl-2, Bcl-xL and Bcl-w (Figure 1A).
Further pharmacological inhibition of two anti-apoptotic
Bcl-2 family members, Bcl-2 and Bcl-xL, was achieved by the
combination of two selective inhibitors at 1:1 ratio, 1 μM
ABT-199 and 1 μM A-1155463 (Figure 1B). These selective in-
hibitors were then tested individually (Figure 1C, D). Given
the higher afﬁnity of ABT-199 and A-1155463 for the respec-
tive hydrophobic clefts of Bcl-2 and Bcl-xL, compared to
ABT-737 (Konopleva et al., 2006; Souers et al., 2013; Tao
et al., 2014), these two inhibitors were used at lower concen-
trations (1 μM vs. 10 μM). Intracellular Ca2+ signals were re-
corded in PACs loaded with Ca2+-sensitive ﬂuorescent probe
Fluo-4. After the baseline signal had been recorded for 200 s,
the cells were treated with the indicated BH3 mimetics for
600 s. Finally, ACh at supramaximal concentration (10 μM)
was used as a positive control for ER Ca2+-store loading.
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Three patterns of Ca2+ responses occurred in PACs treated
with ABT-737 (Figure 1A). While 46% of cells did not show
any Ca2+ response to the mimetic (but responded to ACh;
light grey), 34% produced one or more Ca2+ transients (dark
grey) and 20% of cells developed a prolonged cytosolic Ca2+
plateau (black). Interestingly, a similar response pattern was
obtained when a combination of two selective inhibitors,
ABT-199 together with A-1155463, was used (Figure 1B). In
this case, while 52% of cells did not develop any Ca2+
responses to the inhibitors (but responded to ACh; light
grey), 22% produced one or more Ca2+ transients (dark grey)
and 26% developed an increased cytosolic Ca2+ plateau
(black). Finally, selective inhibition of a single Bcl-2-family
member was tested in PACs. Blocking Bcl-xL with
A-1155463 did not trigger any Ca2+ responses in the majority
of cells tested (76%, light grey), whereas 24% responded with
one or more Ca2+ transients (light grey; Figure 1C). Impor-
tantly, ABT-199, designed to selectively target Bcl-2, did not
Figure 1
Selective pharmacological inhibition of single anti-apoptotic Bcl-2 family members does not induce substantial Ca2+ responses in mouse PACs.
ACh at supramaximal concentration (10 μM) triggers Ca2+ release from the ER and thus can be used to identify responding/live cells. Only PACs
that responded to ACh were included in the analysis of these experiments. Green insets illustrate which Bcl-2 family proteins are targeted by the
used inhibitors in each ﬁgure panel. N, number of independent repeats in the experiments; n, number of independent regions of interest in the
experiment (see the text for details). (A) Sample traces (N = 7, n = 80) show three patterns of [Ca2+]i responses recorded in PACs upon acute ap-
plication of 10 μM ABT-737, an inhibitor of Bcl-2 and Bcl-xL (as indicated in the ﬁgure); 46 % of cells did not show any Ca2+ response (light grey),
34% of cells responded with one or more Ca2+ transients (dark grey), and 20% of cells developed an increased cytosolic Ca2+ plateau (black).
(B) Sample traces (N = 6, n = 46) show three patterns of [Ca2+]i responses recorded in PACs upon acute application of 1 μM ABT-199 (selective
Bcl-2 inhibitor) together with 1 μM A-1155463 (selective Bcl-xL inhibitor); 52 % of cells did not show any Ca2+ response (light grey), 22% of cells
responded with one or more Ca2+ transients (dark grey), and 26% of cells developed an increased cytosolic Ca2+ plateau (black). (C) Sample traces
(N = 6, n = 41) show two patterns of [Ca2+]i responses recorded in PACs upon acute treatment with 1 μM A-1155463. In the majority of cells
(76%), A-115546 did not cause any Ca2+ response (light grey), whereas in approximately 24% of cells, single Ca2+ transients were recorded (dark
grey). (D) Sample trace (N = 5, n = 52) shows lack of Ca2+ response to 1 μMABT-199 in PACs (light grey). (E) Summary of [Ca2+]i response patterns
in PACs to different inhibitors of Bcl-2 family members, colour coding as above. The selective pharmacological Bcl-2 inhibitor ABT-199 does not
have a major effect on intracellular Ca2+ in acinar cells.
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elicit any Ca2+ signals in PACs (light grey; Figure 1D). Even
when ABT-199 was applied at a high dose (10 μM), the vast
majority of cells (89%) did not develop Ca2+ responses and
the remaining 11% of cells responded only with minor oscil-
lations (not shown). Circular diagrams summarizing Ca2+ re-
sponse patterns in PACs to different inhibitors of Bcl-2 family
members are shown in Figure 1E (colour coding corresponds
with the traces). Taken together, these data suggest that selec-
tive inhibition of one Bcl-2 family member does not induce
substantial increases in intracellular Ca2+ (Figure 1C–E). In
contrast, whenmore than one Bcl-2 family protein is targeted
by a BH3 mimetic, the intracellular Ca2+ homeostasis is inﬂu-
enced to a much greater extent (Figure 1A, B, E).
ABT-199, a selective inhibitor of Bcl-2, does not
alter physiological Ca2+ responses in PACs
ABT-199 has recently been approved by the US Food and
Drug Administration as an anti-leukaemic agent. Therefore,
identiﬁcation of its potential side effects prior tomore general
clinical use is of particular importance. ABT-199 at a low nM
concentration (<10 nM) was shown to induce apoptosis in
CLL cells (Souers et al., 2013). Here, we used ABT-199 at a
much higher concentration (1 μM) to test whether it would
affect the oscillatory Ca2+ signals that normally control phys-
iological enzyme secretion in PACs (Figures 2 and 3; see also
Figure 1D, E). Alternations in Ca2+ signals towards more
global and sustained Ca2+ responses could indicate a serious
risk of premature enzyme activation in situ in PACs and thus
a considerable threat of autodigestion and necrosis of the
pancreas, which may develop into acute pancreatitis
(Petersen et al., 2011; Gerasimenko et al., 2014).
Single cell Ca2+ measurements were performed as de-
scribed above. In PACs, ACh at nM concentrations triggers
Ca2+ oscillations, primarily initiated by the IP3Rs and further
ampliﬁed by the ryanodine receptors (RyRs) (Wakui
et al., 1990; Cancela, 2001). Potential effects of ABT-199 on
ACh-elicited Ca2+ release in PACs were assessed in different
Figure 2
ABT-199 does not affect physiological Ca2+ responses to ACh in mouse PACs.N, number of independent repeats in the experiments; n, number of
independent regions of interest in the experiment (see the text for details). (A) Sample trace (N = 5, n = 40) shows physiological [Ca2+]i oscillations
in response to 50 nM ACh recorded after 2 h incubation in the extracellular buffer without ABT-199. (B) Sample trace (N = 5, n = 33) shows phys-
iological [Ca2+]i oscillations in response to 50 nM ACh recorded after 2 h incubation with 1 μM ABT-199. (C) Responses to ACh are quantitatively
analysed by comparing the average [Ca2+]i increase above the baseline levels recorded for 600 s post-treatment: control (blue, N = 5, n = 40,
151.8 ± 14.1 a.u.) or in the presence of 1 μMABT-199 (red,N = 5, n = 33, 136.2 ± 13.9 a.u.). The responses are unaffected by ABT-199. (D) Sample
trace (N = 5, n = 33) shows that physiological [Ca2+]i oscillations evoked by 50 nM ACh are unaffected by acute application of 1 μM ABT-199.
(E) Average traces show [Ca2+]i responses in PACs to a supramaximal dose of ACh (10 μM) in the absence of extracellular Ca
2+. Cells were
incubated for 2 h in the absence (blue trace, N = 6, n = 48) or presence (red trace, N = 7, n = 51) of 1 μM ABT-199. (F) Average traces shown
in (E) are quantitatively analysed by comparing the areas under the traces recorded for 200 s post-treatment: 10 μM ACh alone (blue, n = 48,
115.8 ± 6.8 a.u.) and ACh with ABT-199 (red, n = 51, 100.8 ± 5.7 a.u.). Student’s t-test was applied for statistical analysis.
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experimental settings (Figure 2). First, the inﬂuence of
prolonged incubation (2 h) with ABT-199 on 50 nM ACh-
evoked oscillatory Ca2+ responses was tested and compared
to untreated control. No differences were revealed between
the control (Figure 2A, blue) and the ABT-199-treated PACs
(Figure 2B, red); see also data representing individual areas un-
der the traces (Figure 2C). In addition, acute application of
ABT-199 on top of ACh-elicited Ca2+ oscillations neither af-
fected the frequencies of the responses nor changed their am-
plitudes (Figure 2D). Finally, prolonged incubation (2 h) with
ABT-199 did not alter the global Ca2+ responses to ACh at
supramaximal concentration (10 μM) in PACs (Figure 2E, F).
CCK, at physiologically relevant concentrations (low pM),
induces Ca2+ transients in PACs, which aremediated predom-
inantly by the RyRs (Thorn et al., 1994; Cancela, 2001). To test
whether ABT-199 alters CCK-elicited responses in PACs
(Figure 3), a similar experimental approach as above was
adopted. First, the inﬂuence of a prolonged incubation (2 h)
with ABT-199 on 5 pM CCK-elicited oscillatory Ca2+
responses was tested and compared to an untreated control.
Importantly, no differences were revealed between the
control (Figure 3A, blue) and the ABT-199-treated PACs
(Figure 3B, red); see also data representing individual areas
under the traces (Figure 3C). Next, when ABT-199 was ap-
plied acutely on top of CCK-elicited Ca2+ oscillations, nei-
ther the frequencies nor the amplitudes of the responses
were affected (Figure 3D). Prolonged incubation (2 h) with
ABT-199 (Figure 3E) slightly increased the global Ca2+ re-
leases elicited by CCK at a supramaximal concentration
(10 nM) in PACs (Figure 3E, F). Taken together, these results
indicate that ABT-199 does not substantially affect physio-
logical Ca2+ responses in PACs.
Inhibitors of Bcl-2 family members affect
pathophysiological Ca2+ responses in PACs
BH3mimetics have been developed in order to counteract the
Bcl-2-dependent evasion of apoptosis, common in cancers.
Figure 3
ABT-199 does not affect physiological Ca2+ responses to CCK in mouse PACs.N, number of independent repeats in the experiments; n, number of
independent regions of interest in the experiment (see the text for details). (A) Sample trace (N = 7, n = 66) shows [Ca2+]i responses to 5 pM CCK
recorded after 2 h incubation in the extracellular buffer without ABT-199. (B) Sample trace (N = 8, n = 58) shows physiological [Ca2+]i oscillations
in response to 5 pM CCK recorded after 2 h incubation with 1 μMABT-199. (C) Responses to 5 pM CCK are quantitatively analysed by comparing
the average [Ca2+]i increase above the baseline levels recorded for 800 s post-treatment: control (blue, N = 7, n = 66, 55.4 ± 4.5 a.u.) or in the
presence of 1 μMABT-199 (red, N = 8, n = 58, 54.3 ± 4.3 a.u.). The responses are unaffected by ABT-199. (D) Sample trace (N = 5, n = 100) shows
that physiological [Ca2+]i oscillations evoked by 5 pM CCK are unaffected by acute application of ABT-199. (E) Average traces show [Ca
2+]i re-
sponses in PACs to a supramaximal dose of CCK (10 nM) in the absence of extracellular Ca2+. Cells were incubated for 2 h in the absence (blue
trace, N = 5, n = 61) or presence (red trace, N = 8, n = 102) of 1 μM ABT-199. (F) Average traces shown in (E) are quantitatively analysed by com-
paring the areas under the traces recorded for 200 s post-treatment: 10 nM CCK alone (blue,N = 5, n = 61, 73.8 ± 5.7 a.u.) and CCK with ABT-199
(red, N = 8, n = 102, 92.5 ± 3.6 a.u.). Student’s t-test was applied for statistical analysis.
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Normal cells, such as PACs, are much less dependent on anti-
apoptotic Bcl-2 family members than cancer cells. However,
even in non-transformed cells, pathophysiological stimu-
lants that trigger cell death could inﬂuence the balance be-
tween the pro- and anti-apoptotic Bcl-2 proteins and thus
may ‘prime these cells for death’. Therefore, pathophysiolog-
ical stress may reveal additional effects of a BH3 mimetic that
do not surface under physiological conditions.
To test whether inhibitors of Bcl-2 proteins would modu-
late Ca2+ signals in PACs under a pathophysiological stimu-
lus, the cells were incubated (2 h) with different BH3
mimetics (concentrations as in Figure 1) and then treated
acutely with TLC-S or menadione. Single-cell Ca2+ measure-
ments in PACs were performed as described above. The bile
acid TLC-S, known to induce pathophysiological Ca2+ signals
and necrosis in PACs (Gerasimenko et al., 2006), was used
here as an initiator of necrotic stress (Figure 4A). An apoptotic
stimulus was supplied by menadione, an agent with
vitamin K activity, which triggers mitochondrial stress via
excessive production of ROS (Figure 4B) (Monks et al., 1992;
Gerasimenko et al., 2002). Menadione was also shown to
elicit pathophysiological Ca2+ signals in PACs, associated
with the induction of apoptosis (Gerasimenko et al., 2002).
Substantial elevations in cytosolic Ca2+ in PACs were in-
duced by 200 μM TLC-S (Figure 4A). These elevations were
reduced by the Bcl-2 inhibitor ABT-199 (P < 0.05), whereas
A-1155463 (blocker of Bcl-xL) potentiated TLC-S-elicited
Ca2+ release (P < 0.05). Interestingly, these two opposite
effects cancelled out when ABT-199 and A-1155463 were
applied simultaneously. Under the inhibition of a wide range
of Bcl-2 family proteins by ABT-737, TLC-S-induced Ca2+
responses were potentiated (P < 0.05).
A similar experimental approach was used to test the ef-
fects of BH3 mimetics on 60 μMmenadione-elicited Ca2+ ele-
vations in PACs (Figure 4B). ABT-199 alone, despite failing to
cause a clear reduction in menadione-driven Ca2+ responses,
deﬁnitely did not potentiate them. In contrast, A-1155463
(when applied on its own or simultaneously with ABT-199),
as well as ABT-737, both increased the pathophysiological
Ca2+ elevations induced by menadione (P < 0.05). Taken to-
gether, pharmacological inhibition of Bcl-xL via its hydro-
phobic cleft appears to increase pathophysiological Ca2+
responses, whereas inhibition of Bcl-2 does not have a major
impact on Ca2+ homeostasis both in physiology and pathol-
ogy. Since ABT-199 does not exacerbate pathophysiological
Ca2+ signals, it may have a more advantageous safety proﬁle
compared to inhibitors that target Bcl-xL.
BH3 mimetics do not aggravate apoptotic or
necrotic cell death in PACs
As shown above, the new generation of BH3mimetics may al-
ter TLC-S- or menadione-elicited Ca2+ responses in PACs.
Since Ca2+ release is associated with the induction of necrosis
and apoptosis, application of Bcl-2 protein inhibitors may
modulate PAC death. To determine this, PACs were incu-
bated for 2 h with either TLC-S (200 μM) or menadione
(60 μM) in the presence of BH3 mimetics or appropriate vehi-
cles (Figure 5A–C). Annexin V-FITC/PI staining was used to
assess the extent of cell death. The number of live (grey), ap-
optotic (blue), necrotic (red) cells as well as secondary
necrosis (pink) was determined and is presented in Figure 5.
Importantly, treatment with the selective BH3 mimetics did
not induce cell death in PACs, indicating that dependence
on Bcl-2/Bcl-xL for survival is rather limited in these cells
(Figure 5A). Also, the presence of BH3 mimetics did not sig-
niﬁcantly alter TLC-S- (Figure 5B) or menadione-induced
(Figure 5C) cell death in PACs.
We further scrutinized the effects of ABT-199, given its
use in clinical settings. First, a longer (4 h) incubation with
ABT-199 (1 μM) did not potentiate the increased cell death
that spontaneously occurred in PACs maintained in vitro
for longer periods (Figure 5D). Second, we also determined
whether the ABT-199 concentration (1 μM) and duration
of the treatment (2 h) used in the PAC experiments could
kill effectively Bcl-2-dependent cancer cells known to be
sensitive to ABT-199 (Anderson et al., 2016; Vervloessem
et al., 2017a). For this, two DLBCL cell lines, OCI-LY-1 and
Ri-1, and primary CLL lymphocytes obtained from ﬁve dif-
ferent patients, were treated with 1 μM of ABT-199 for 2, 4
or 6 h (Figure 5E, F). The number of living cells was deter-
mined using Alexa Fluor™ 488 Annexin V/7-AAD or FITC
Annexin V/PI staining. In all cell lines and patient samples
tested, a 2 h treatment with 1 μM ABT-199 showed exten-
sive cell death that was not dramatically increased by
extending the duration of the treatment. This suggests a
near maximal effect of ABT-199 at 1 μM in these cancer cells
already after 2 h. Taken together, these results indicate that
selective Bcl-2 protein family inhibitors neither provoke cell
death by themselves nor aggravate cell death induced by
pathophysiological stimuli in PACs. For ABT-199, we vali-
dated that the concentrations/time periods used were capa-
ble of inducing cell death in Bcl-2-dependent cancers.
Selective inhibition of Bcl-2 affects cytosolic
Ca2+ extrusion
Since Bcl-2 was previously found to regulate cytosolic Ca2+
extrusion in PACs by modulating plasma membrane
Ca2+ ATPase (PMCA) activity (Ferdek et al., 2012), we
wanted to address whether pharmacological inhibition of
Bcl-2 by ABT-199 could affect this process. In order to mea-
sure Ca2+ extrusion, a protocol similar to that described be-
fore (Ferdek et al., 2012) was used. PACs pretreated for 2 h
with 1 μMABT-199 or incubated for the same amount of time
in extracellular buffer (control) were exposed to Tg, a potent
SERCA inhibitor, in Ca2+-free solution (Figure 6A, B). The ap-
plication of Tg results in the emptying of the ER Ca2+ stores
(manifested as the initial response in Figure 6A, B). Increasing
extracellular Ca2+ concentration to 10 mM induced Ca2+ in-
ﬂux to the cytosol via store-operated Ca2+ channels, which
are opened upon ER Ca2+ depletion. Once a [Ca2+]i plateau
was established (the second response in Figure 6A, B), extra-
cellular Ca2+ was removed again causing the [Ca2+]i to decline
towards the baseline levels. Since Ca2+ uptake into the ER is
inhibited by Tg, the clearance of [Ca2+]i, in Ca
2+-free solution
reﬂects Ca2+ extrusion across the plasma membrane, mainly
via PMCA. Despite a substantial variability in cytosolic Ca2+
extrusion rates in both control and ABT-199-treated cells,
the apparent rate of extrusion was on average slightly faster
in the presence of ABT-199 (Figure 6A, B, sample traces).
The distribution of the linear ﬁts to the extrusion rates in
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ABT-199-treated cells was shifted towards those with faster
declines (Figure 6C). This difference is well reﬂected by a
lower t1/2 (72.7 ± 4.2 s) for ABT-199-treated PACs compared
to control cells (87.7 ± 5.7 s), which translates into a shorter
time required for the ﬂuorescence of the Ca2+ indicator to de-
crease by half the difference between the [Ca2+]i plateau and
the baseline (Figure 6D). Although this effect is relatively mi-
nor and also much less prominent to that observed upon the
complete loss of Bcl-2 (Ferdek et al., 2012), a potentiation of
cytosolic Ca2+ extrusion may underlie the modest reduction
of pathophysiological Ca2+ responses evoked by TLC-S in
the presence of ABT-199 (Figure 4A).
Figure 4
ABT-199 does not potentiate pathophysiological Ca2+ responses evoked by TLC-S or menadione. N, number of independent repeats in the
experiments; n, number of independent regions of interest in the experiment (see the text for details). (A) Dot chart shows response areas cal-
culated for the ﬁrst 1000 s of [Ca2+]i responses (and corresponding traces below show typical [Ca
2+]i responses) recorded in mouse PACs to
200 μM TLC-S alone (Ctrl N = 6, n = 78, 196.8 ± 18.8 a.u.) or in the presence of 1 μM ABT-199 (N = 6, n = 93, 130.3 ± 10.0 a.u.), 1 μM
A-1155463 (N = 5, n = 55, 264.2 ± 10.4 a.u.), 1 μM ABT-199 together with 1 μM A-1155463 (N = 5, n = 61, 213.1 ± 10.4 a.u.) or 10 μM
ABT-737 (N = 5, n = 65, 243.0 ± 12.9 a.u.). Cells were incubated for 2 h in the buffer with or without the appropriate inhibitor/s. One-
way ANOVA together with the Bonferroni’s post hoc test were used for the statistical analysis; #, signiﬁcant versus treatment with TLC-S; ¶,
signiﬁcant versus treatment with TLC-S + ABT-199. (B) Dot chart shows response areas calculated for the ﬁrst 1000 s of [Ca2+]i responses
(and corresponding traces below show typical [Ca2+]i responses) recorded in mouse PACs to 60 μM menadione alone (Ctrl N = 6, n = 45,
112.0 ± 11.2 a.u.) or in the presence of 1 μM ABT-199 (N = 5, n = 42, 96.2 ± 11.1 a.u.), 1 μM A-1155463 (N = 5, n = 40, 159.5 ± 15.7 a.u.),
1 μM ABT-199 together with 1 μM A-1155463 (N = 5, n = 33, 176.4 ± 16.0 a.u.) or 10 μM ABT-737 (N = 6, n = 56, 151.9 ± 10.1 a.u.). Cells
were incubated for 2 h in the buffer with or without the appropriate inhibitor/s. Scale bars for both: vertical 0.5 F/F0 and horizontal 200 s.
Kruskal–Wallis one-way ANOVA (a nonparametric test) was used here for statistical analysis; #, signiﬁcant versus treatment with menadione;
¶, signiﬁcant versus treatment with menadione + ABT-199.
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Discussion
It is very well established that the Bcl-2 family proteins play a
role in the regulation of intracellular Ca2+ homeostasis
(Vervliet et al., 2016). Although primarily associated with
the mitochondrial membranes, these proteins also reside in
other cell compartments such as the cytosol, the ER and the
nuclear envelope (Krajewski et al., 1993). At the ER (the main
intracellular Ca2+ store), the anti-apoptotic Bcl-2-family
members regulate several proteins involved in Ca2+ signalling
(Vervliet et al., 2016), including the IP3R (Rong et al., 2008,
2009; Ivanova et al., 2014). The binding of Bcl-2 and Bcl-xL
to the C-terminal region of IP3R results in sensitization of
the receptor and triggers pro-survival Ca2+ oscillations (White
et al., 2005; Eckenrode et al., 2010). Bcl-2 also interacts with
the central regulatory domain of IP3R via its BH4 domain
Figure 5
ABT-199 applied under conditions capable of inducing cell death in Bcl-2-dependent cancer cells neither triggers nor potentiates cell death in
PACs. (A–C) Bar charts (mean ± SEM) showing cell death in the absence of an additional trigger (A), induced by 2 h treatment with 200 μM
TLC-S (B) or induced by 2 h treatment with 60 μM menadione (C) in mouse PACs in the presence or absence of 1 μM ABT-199, 1 μM A-
1155463, 1 μMABT-199 together with 1 μMA-1155463 or by 10 μMABT-737 (N = 5, n = 75). Grey bars represent live cells; blue, apoptotic cells;
pink, secondary necrosis; and red, necrosis. Kruskal–Wallis one-way ANOVA (a nonparametric test) was used here for statistical analysis; *P< 0.05,
signiﬁcant versus treatment with ABT-199 (apoptosis only). (D) Bar chart (mean ± SEM) showing cell death assessed after 4 h incubation with or
without 1 μMABT-199 (N = 5); colour coding and statistical analysis as above. (E) Dot chart showing the percentage of live human DLBCL cell lines
(OCI-LY1 and Ri-1) in the presence or absence of 1 μM ABT-199 (N = 5) after 2, 4 or 6 h. Student’s t-test was applied for statistical analysis;
*P < 0.05. (F) Before–after scatter plots showing the percentage of live CD5+CD19+ cells obtained from CLL patients, in the presence or absence
of 1 μM ABT-199 (N = 5) following a 2, 4 or 6 h incubation. Student’s t-test was applied for statistical analysis; *P < 0.05.
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thereby inhibiting excessive pro-apoptotic Ca2+ release
(Chen et al., 2004; Rong et al., 2009; Monaco et al., 2012). Be-
sides IP3Rs, the anti-apoptotic Bcl-2 proteins also regulate in-
tracellular Ca2+ handling via RyRs (Vervliet et al., 2014),
SERCA (Kuo et al., 1998) and Bax inhibitor-1 (Xu et al.,
2008) at the ER, as well as PMCA (Ferdek et al., 2012) and
the mitochondrial voltage-dependent anion channel (Arbel
and Shoshan-Barmatz, 2010). Therefore, agents that bind to
and inhibit the Bcl-2-family members may affect some of
the above interactions and indirectly modulate intracellular
Ca2+ homeostasis.
Inhibition of the anti-apoptotic Bcl-2 members by the
early generation BH3 mimetics, BH3I-20 and HA14-1, was as-
sociated with global and sustained Ca2+ responses induced
in normal mouse PACs and in the rat pancreatic cancer cell
line AR42J (Gerasimenko et al., 2010). These BH3 mimetic-
elicited responses were later shown to be dependent on Bax,
but not Bak or Bcl-2 (Ferdek et al., 2017). Moreover, HA14-1
was demonstrated to inhibit SERCA and deplete ER Ca2+
stores, causing the ER stress-mediated cell death (Hermanson
et al., 2009; Akl et al., 2013).
This study demonstrates that selective inhibition of Bcl-2
by ABT-199 neither triggers substantial intracellular Ca2+ re-
lease in PACs (Figure 1) nor affects Ca2+ responses elicited
by endogenous agonists at physiologically relevant concen-
trations (Figures 2 and 3). Targeted inhibition of Bcl-xL by
A-1155463 only had a minor effect on the intracellular Ca2+
homeostasis, occasionally inducing infrequent Ca2+ tran-
sients in PACs (Figure 1C). In contrast, inhibition of more
than one Bcl-2 family member via simultaneous application
of ABT-199 and A-1155463 (Figure 1B) or by ABT-737 (blocker
of Bcl-2, Bcl-xL and Bcl-w; Figure 1A) triggered sporadic intra-
cellular Ca2+ rises in PACs or a prolonged Ca2+ plateau. This
suggests that the toxic effects of BH3 mimetics on Ca2+ asso-
ciated with the inhibition of a wide range of the anti-
apoptotic Bcl-2 proteins could be avoided by selectively
targeting only one family member, speciﬁcally Bcl-2 itself
(Figure 1E). Although it was previously shown that ABT-199
does not alter intracellular Ca2+ signalling in cell lines, in-
cluding Bcl-2-dependent DLBCL cancer cell models
(Vervloessem et al., 2017b), this study is one of the ﬁrst few
to extend that ﬁnding to non-transformed primary cells.
Given the toxic effects of early generation BH3 mimetics on
PACs, it was particularly timely and relevant to scrutinize
the impact of the newly approved drug ABT-199 on physio-
logical and pathophysiological signalling in the exocrine
pancreatic system and thus to elucidate potential
pancreatoxic effects (Figures 1–5).
ABT-199 did not alter Ca2+ responses elicited by physio-
logical or supramaximal concentrations of ACh (Figure 2).
These responses are primarily initiated by IP3R-mediated
Ca2+ release from the ER and further ampliﬁed by RyRs
(Wakui et al., 1990; Cancela, 2001). Physiological CCK sig-
nalling, mediated by RyRs, was also essentially unaffected
by ABT-199 (Figure 3). A minor effect on CCK responses
was only present at very high concentrations of the secreta-
gogue. These results are in line with our previous work in
cell models where we showed that binding to and regula-
tion of IP3Rs and RyRs by Bcl-2 is independent of its hydro-
phobic cleft (Vervliet et al., 2015; Ivanova et al., 2016), and
thus, it is unlikely to be affected by BH3 mimetics that inter-
act with this site.
Although inhibition of Bcl-xL by A-1155463 or pan-
inhibition of Bcl-2/Bcl-xL/Bcl-w by ABT-737 potentiated
pathophysiological Ca2+ responses induced by TLC-S or men-
adione, selective inhibition of Bcl-2 by ABT-199 did not
(Figure 4). In fact, TLC-S-elicited Ca2+ responses were even re-
duced in the presence of ABT-199 (Figure 4A). This might be
due to a modest effect of ABT-199 on cytosolic Ca2+ extrusion
(Figure 6), which is almost exclusively dependent on PMCA
Figure 6
ABT-199 affects cytosolic Ca2+ extrusion in PACs. N, number of inde-
pendent repeats in the experiments; n, number of independent re-
gions of interest in the experiment (see the text for details).
(A) Sample [Ca2+]i trace recorded in a PAC pre-incubated for 2 h in
the extracellular buffer (control). Application of Tg in the absence
of external Ca2+ resulted in the depletion of the ER Ca2+ store. Subse-
quent exposure to an external solution containing 10 mM Ca2+ for a
period of 200 s triggered store-operated Ca2+ entry. Returning the
PACs to a Ca2+-free external solution again reduces elevated [Ca2+]
I, which in the presence of Tg is due to Ca
2+ extrusion across the
plasma membrane. (B) Sample [Ca2+]i trace recorded in a PAC pre-
incubated for 2 h with 1 μM ABT-199. The same protocol was used
as above in (A). (C) Linear ﬁts calculated to the extrusion phases re-
corded in control (blue) and ABT-199-treated (red) cells (as in A
and B). Scale bars: x axis, 20 s; and y axis, 0.4 F/F0 (Fluo-4). (D) Dot chart
shows the half-times (t1/2) of cytosolic Ca
2+ extrusion recorded for
control (blue, N = 7, n = 48, 87.8 ± 5.7 s) and ABT-199-treated PACs
(red, N = 7, n = 46, 72.7 ± 4.2 s) as shown in (A) and (B) respectively.
Student’s t-test was applied for statistical analysis.
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activity in PACs (Petersen, 2003; Ferdek et al., 2012). As
shown previously, Bcl-2 has been found to have an inhibi-
tory effect on PMCA in PACs (Ferdek et al., 2012). ABT-199
appears to interfere with this function of Bcl-2, thereby
enhancing Ca2+ extrusion by alleviating Bcl-2’s inhibitory
effect on PMCA.
The moderate suppression of pathological Ca2+ signals by
ABT-199 was reversed by A-1155463, when PACs were pre-
incubated with both inhibitors before application of TLC-S,
indicating that the effects on Ca2+ associated with Bcl-xL
inhibition dominate over those triggered by inhibition of
Bcl-2 (Figure 4A). Since A-1155463 interacts with the hydro-
phobic cleft of Bcl-xL, this site appears to play a role in the
regulation of intracellular Ca2+ signalling in response to path-
ophysiological stimulants. The mechanisms remain unclear,
although it may relate to interference by these drugs of
Bcl-xL-dependent regulation of Ca2+-release systems like
IP3Rs (Yang et al., 2016).
Despite the aforementioned effects on pathophysiologi-
cal Ca2+ responses induced by TLC-S and menadione
(Figure 4), neither of the inhibitors used in the study mark-
edly affected cell death in PACs (Figure 5A,D). These results
may suggest that the relatively small effects of ABT-199,
A-115563 or ABT-737 on Ca2+ homeostasis in PACs are insuf-
ﬁcient to increase the sensitivity of normal cells to cell death
inducers. This ﬁnding could be particularly relevant to the
situation when a BH3 mimetic is used in combination with
other chemotherapeutic agents. Such combined therapies
are currently undergoing clinical trials (Ferdek and
Jakubowska, 2017). It is important to note that with the con-
ditions applied (1 μMABT-199 for 2 h) ABT-199 was potent at
inducing cell death in Bcl-2-dependent cancer cells, includ-
ing the activated B-cell like lymphoma cancer cell line Ri-1,
the germinal centre B-cell-like lymphoma cell line OCI-LY-1
and primary cells derived from CLL patients (Figure 5E,F).
In conclusion, we report that selective inhibition of Bcl-2
by ABT-199, apart from having a modest effect on cytosolic
Ca2+ extrusion (Figure 6), does not either dramatically alter
intracellular Ca2+ signals on its own (Figure 1) or in response
to physiological (Figures 2 and 3) and pathophysiological
stimuli in isolated PACs (Figure 4). As a consequence, ABT-
199 does not sensitize non-transformed healthy PACs to cell
death (Figure 5). Therefore, we conclude that since ABT-199
does not substantially affect intracellular Ca2+ homeostasis
or sensitize healthy PACs to inducers of cell death, it should
be safe for the pancreas when used in therapy for leukaemia.
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